STAT Plus: Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations
Rise and shine, everyone, another busy day is on the way. We can tell because once again, the shortest person dashed off to the local schoolhouse. Ring, ring, goes the bell. As for us, the coffee kettle is whistling away as we ready still more cups of stimulation. Our choice today is cinnamon swirl. Feel free to join us or, if you prefer, reach for a water bottle. Meanwhile, here are a few tidbits to help you move down the tracks. Hope you have a splendid day and, as always, please do keep in touch …
Drug makers and their trade groups shelled out millions of dollars to lobby Congress as it considered legislation aimed at reining in skyrocketing drug prices, The Hill writes, citing new lobbying disclosure reports. PhRMA — the trade group representing brand-name drug companies — spent $6.2 million on lobbying in the third quarter of 2019, which ran from July through the end of September. That was $240,000 more than it spent during the same time frame last year.
Continue to STAT Plus to read the full story…
